Posted by Michael Wonder on 19 Sep 2018
Merck slashes key cancer drug price for China
19 September 2018 - U.S. pharmaceutical giant MSD will cut the price of one of its core cancer drugs for China launch, following a move by rival BMS, which cut the price of the drug in half for the lucrative market.
MSD has developed a patient financial assistance program for Keytruda, an innovative molecule with application for melanoma and lung cancer, Caixin learned. Patients who pay for three months of treatment will get the next three months free, resulting in a 50% price reduction.
Even though it set the price reduction plan, MSD hasn’t disclosed the market price for Keytruda in China. The company received a sales go-ahead from Chinese drug regulators in July.
